Advertisement


Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

2015 ASCO Annual Meeting

Advertisement

Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).



Related Videos

Breast Cancer

Jame Abraham, MD, Summarizes Results From the NeoSphere and ExteNET Trials for Breast Cancer

Jame Abraham, MD, of the Cleveland Clinic discusses analyses of two trials for locally advanced, inflammatory, or early HER2-positive breast cancer using docetaxel, trastuzumab, pertuzumab, and neratinib (Abstracts 505 and 508).

Prostate Cancer

Howard M. Sandler, MD, and Christopher Sweeney, MBBS, on Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discuss the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).

Skin Cancer

Andrew James Martin, PhD, on Oral Nicotinamide for Nonmelanoma Skin Cancer

Andrew James Martin, PhD, of NHMRC Clinical Trials Centre, University of Sydney, discusses a form of vitamin B3 that reduced the incidence of new nonmelanoma skin cancers in high-risk patients (Abstract 9000).

Issues in Oncology
Cost of Care

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Charles L. Bennett, MD, PhD, MPP of the University of South Carolina College of Pharmacy, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss the emerging and future benefits of biosimilars.

Breast Cancer

Richard G. Margolese, MD, and Robert W. Carlson, MD, on NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Robert W. Carlson, MD, of the National Comprehensive Cancer Network, and Richard G. Margolese, MD, of McGill University, discuss the improvement in breast cancer–free interval with anastrozole vs tamoxifen in patients with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract LBA500).

Advertisement

Advertisement




Advertisement